Treatment of Desmoid Tumor of Small Intestine When Active Surveillance Has Failed

In patients with desmoid tumor of the small intestine, active surveillance is the initial approach. When the tumor fails to stabilize or spontaneously regress on imaging, escalation to systemic treatment becomes the next clinical step.

Prior Treatment & Failure Condition

The preceding approach — active surveillance with serial MRI (or CT) every 3–6 months combined with NSAIDs for pain management — targets stabilization or spontaneous regression of the tumor on imaging. When that goal is not achieved and disease progresses or fails to regress, this systemic protocol is indicated.

Next-Line Treatment: Systemic Therapy

Systemic medical options — including targeted therapies and cytotoxic chemotherapy regimens — form the basis of management at this stage; the full approach, selection criteria, and sequencing are available in the complete protocol.

Treatment goals at this stage include objective tumor response (partial response with regression) or stable disease on imaging, alongside symptomatic improvement.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/cncr.34332

Current options for medical management include tyrosine kinase inhibitors as well as more conventional cytotoxic chemotherapy (e.g., anthracycline-based or methotrexate-based regimens).
Of note, unlike cytotoxic chemotherapy, in which treatment cycles are limited, TKIs are generally used continuously until intolerance develops or disease progresses.
Typically, low-dose methotrexate plus vinblastine or vinorelbine, or, alternatively, a conventional anthracycline-containing regimen is associated with disease control rates (DCRs) of 64%–100%.
Among the patients who were evaluable for pain, 74% had symptomatic improvement after 3 months.

View source ↗